Objectives This post hoc analysis of TIOtropium Safety and Performance In Respimat (TIOSPIR) evaluated safety and exacerbation efficacy in patients with stable (≥2 months) use of tiotropium HandiHaler ...

Hanmi Pharmaceutical signed an agreement last Tuesday with Boehringer Ingelheim Korea to distribute and promote three chronic obstructive pulmonary disease (COPD) treatments nationwide: Spiriva ...

Boehringer Ingelheim today announced the launch of its new direct-to-consumer platform, “Boehringer Ingelheim Access.” The platform will offer a convenient way for patients in the U.S. to order and ...

Adding the LAMA tiotropium Respimat inhaler to combination LABA/ICS inhaler may reduce the need for rescue oral steroids. A noticeable benefit on quality of life is unlikely, and we couldn't tell if ...

Stiolto Respimat (tiotropium bromide/olodaterol) is an inhaled medication for the treatment of chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. However, it is not indicated for ...

SPIRIVA RESPIMAT, 2.5 mcg, and SPIRIVA HANDIHALER are long-term, once-daily, prescription maintenance medicines used to control symptoms of chronic obstructive pulmonary disease (COPD) by relaxing ...

When I read the news that three out of four manufacturers of asthma and COPD inhalers have decided to cap the price to the patient to no more than $35 a month, it came as a shockingly pleasant ...

Boehringer Ingelheim Pharmaceuticals was hit with an antitrust class action on April 29 in Connecticut District Court. The suit accuses the company of undermining generic competition in the market for ...

One of the top inhaler manufacturers in the U.S. announced plans on Thursday to cap the out-of-pocket cost of all its inhalers at $35 a month starting later this year after facing Democratic ire.

The pooled safety database consisted of 30 completed clinical trials as of September 2008 in the tiotropium (Boehringer Ingelheim GmbH; Ingelheim, Germany) project database. For inclusion, all trials ...